Drugs / Tislelizhu
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05481775 Background | Apr 2022 → Apr 2025 | non-small cell lung carcinoma | Sun Yat-sen University | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tislelizhu | “consolidation Immunotherapy (Tislelizhu 200mg iv. drip, Q3W, up to 12 months.)” NCT05481775 ↗ |
| Route | Intravenous | “consolidation Immunotherapy (Tislelizhu 200mg iv. drip, Q3W, up to 12 months.)” NCT05481775 ↗ |